Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man
Observational studyHumansOther animalsWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 250 stroke patients in neurorehabilitation, inpatient or outpatient; plus rats with middle cerebral artery occlusion
- Dose used in the study
- Co-ultramicronised PEA-luteolin 10:1 (Glialia) for 60 days in patients; post-ischaemia dosing in rats
- Duration
- 60 days, assessed at baseline and 30 days
- What was measured
- Neurological status, cognitive impairment, spasticity, pain and independence in daily living in patients; oedema, infarct volume, behaviour and inflammatory markers in rats
What the authors reported
In rats the combination reduced oedema and infarct size and improved behaviour. In patients every index improved between baseline and 30 days, which the authors describe as more than expected from spontaneous recovery.
Limits of this study
The human arm is observational with no control group in people who were also receiving rehabilitation, where recovery over 30 days is the norm. The authors themselves call for controlled trials. Two authors are linked to Epitech, which makes Glialia. The animal arm cannot stand in for a controlled human trial.
Source
PubMed 26706245 · doi:10.1007/s12975-015-0440-8
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.